2024 World Conference on Lung Cancer (WCLC) - Posters-P3.08F.06 PLATINUM Trial: Preliminary Analysis of Lazertinib Therapy in Locally Advanced, Unresectable, EGFR Mutation(+) NSCLC Following CCRT

P3.08F.06 PLATINUM Trial: Preliminary Analysis of Lazertinib Therapy in Locally Advanced, Unresectable, EGFR Mutation(+) NSCLC Following CCRT

Back to course

Pdf Summary

The PLATINUM trial is a preliminary analysis focused on evaluating lazertinib, a third-generation EGFR-TKI, as consolidation therapy for patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (NSCLC) who have not shown disease progression following definitive platinum-based chemoradiation therapy (CCRT). The trial enrolled 25 patients, primarily female (56%), aged mostly above 65 years (64%), who had either exon 19 deletions (44%) or L858R mutations (56%) in the EGFR gene. All participants had adenocarcinoma histology and had not received prior EGFR-TKI treatment.<br /><br />Participants underwent CCRT, with lazertinib therapy starting within 1–42 days post-CCRT. The drug is noted for its efficacy in penetrating the blood-brain barrier and selectively targeting EGFR sensitizing and T790M mutations.<br /><br />Safety results indicated that 88% experienced adverse events (AEs), with 32% facing Grade 3-4 AEs. Treatment-related AEs were reported by 80%, leading to discontinuation in 28% of cases. Serious adverse events (SAEs) affected 28% of participants, with no treatment-related deaths recorded.<br /><br />This trial highlights lazertinib as a promising consolidation therapy following chemoradiation in EGFR mutation-positive NSCLC, showing clinically meaningful efficacy. Comparisons are made with previous studies, notably the PACIFIC study, which used durvalumab in a broader NSCLC population and demonstrated limited benefits for those with EGFR mutations. Lazertinib's efficacy, exhibited in this study, echoes findings in other studies like the LAURA study, where osimertinib prolonged progression-free survival post-CCRT.<br /><br />In summary, while further research is needed, lazertinib shows potential as an effective therapy for unresectable stage III EGFR mutation-positive NSCLC patients post-CCRT, offering an improved safety and efficacy profile over previous treatments.

Asset Subtitle

Sung Yong Lee

Meta Tag

Speaker Sung Yong Lee

Topic Local-Regional NSCLC

Keywords

PLATINUM trial

lazertinib

EGFR-TKI

non-small cell lung cancer

chemoradiation therapy

EGFR mutation

adverse events

consolidation therapy

blood-brain barrier

osimertinib